Amidst the news of the withdrawal of the Covishield vaccine from the market, two Indian studies suggest that the vaccine's benefits may outweigh its risks.
A study conducted by Assam Medical College Hospital, with support from an ICMR-recognized laboratory, revealed that 55% of Covishield recipients encountered only mild side effects, such as fever and headache, within a week of receiving the first dose. Moreover, the study found no long-term adverse effects after the year's end.
In a separate study, doctors from Kozhikode have conducted a distinct study indicating that the risks associated with the vaccine are negligible when weighed against its benefits.
Amidst the optimistic findings, it's crucial to acknowledge concerns about a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS), which was highlighted in a UK court case involving AstraZeneca's COVID-19 vaccine, marketed as Covishield in India and developed in partnership with the University of Oxford.
The Indian Express- quoted that, it is evident that the benefits of the Covishield vaccine in preventing severe COVID-19 disease and saving lives significantly outweigh the extremely low risk of rare adverse effects like Thrombosis with Thrombocytopenia Syndrome or TTS.
The research demonstrates that TTS is extremely rare. While any potential adverse reaction is understandably worrisome for patients, we cannot overlook the overwhelmingly positive effect this vaccine has had in significantly reducing COVID-19 hospitalizations, critical care requirements, and ultimately saving lives.
Health Disclaimer: editorji does not provide medical advice. The information, including but not limited to, text, graphics, images and other material contained in this story are for informational purposes only. No material in this video is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider.
Also watch: AstraZeneca says withdrawing Covid-19 vaccine globally after admitting rare side effect